Product
Mayzent
Aliases
MAYZENT
Name
MAYZENT
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
1 document
Indication
Secondary Progressive Multiple SclerosisIndication
Secondary-progressive Multiple SclerosisClinical trial
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)Status: Completed, Estimated PCD: 2023-08-30
Clinical trial
Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple SclerosisStatus: Completed, Estimated PCD: 2023-06-01
Document
DailyMed Label: MAYZENTOrganization
Novartis Pharmaceuticals Corporation